Gilead Sciences is a global biopharmaceutical company built on antiviral medicine. Its core business is discovering, developing and selling patent-protected drugs for HIV — where it is the world leader with roughly three-quarters of the market via Biktarvy and the newer twice-yearly injectable lenacapavir (Yeztugo) — alongside hepatitis (Epclusa, Harvoni), liver disease (Livdelzi) and a growing oncology / cell-therapy arm (Trodelvy, Yescarta, Tecartus CAR-T). Its distinctive edge is a durable, high-margin HIV franchise: a deep patent estate, ~79% gross margins, prodigious free cash flow, and dominant scale few rivals can match. The near-term story is defined by two forces — the durability of that HIV cash engine (flagship Biktarvy just had its US patent protection extended to 2036) and the ramp of lenacapavir into HIV prevention — set against the overhang of US drug-pricing policy (IRA Medicare negotiation). Think of it as a cash-cow antiviral leader trading at a modest multiple while it works to re-accelerate growth.
Lifecycle & sector: Mature, cash-generative large-cap biopharma (Healthcare / Drug Manufacturers – General). Scored on the mature-pharma lens: R&D efficiency, patent-cliff exposure, revenue durability, ROIC and dividend sustainability — not growth multiples.
| Sub-signal | Value | Sector read | Score |
|---|---|---|---|
| Gross margin (TTM) | 79.4% | Elite for pharma (>75%) | 88 |
| Operating margin (TTM) | 38.3% | Top-tier | 82 |
| FCF margin | ~34% (FCF/sh $8.24) | Exceptional cash conversion | 85 |
| Balance sheet | Net debt/EBITDA ~1.0x, int. cover 11.3x, current 1.97 | Healthy | 78 |
| ROE / ROIC | ROE ~39%, ROIC ~20% | > WACC — value-creating (leverage-aided) | 78 |
| Revenue trajectory | TTM ~$29.7B, HIV growing, HCV declining | Low-single-digit, durable | 62 |
Competitive Moat — five dimensions (avg approx 68):
| Dimension | Score | Basis |
|---|---|---|
| Pricing power | 70 | Patent-protected HIV franchise; capped by IRA Medicare price negotiation |
| Network effects | 50 | N/A to pharma (neutral) |
| Switching costs | 70 | HIV regimens are sticky (adherence, physician inertia); trimmed by emerging once-weekly oral rivals |
| Cost advantage | 72 | Scale leader in HIV (~75%+ share); efficient manufacturing/distribution |
| Intangible assets | 80 | Patent estate (Biktarvy to 2036, lenacapavir composition), brand, FDA approvals, regulatory barriers |
| Rival | Threat type | Share trajectory | Moat-erosion vector |
|---|---|---|---|
| GSK / ViiV Healthcare | Direct HIV — long-acting injectables (Cabenuva, Apretude every-2-month) | Gilead stable to gaining in prevention | Yeztugo's twice-yearly dosing beats ViiV's cadence, defending PrEP share |
| Merck & Co. | Once-weekly oral islatravir/doravirine (partly a GILD collaboration) | Stable now; medium-term threat | Next-gen oral could pressure Biktarvy treatment share post-2030 |
| Generic makers | Biktarvy biosimilars/generics | Deferred | US entry blocked to Apr 2036 by settlements |
| AbbVie / BMS | Oncology & immunology (non-HIV) | Gilead lagging in oncology | Trodelvy lung setback; CAR-T competitive |
Net effect: HIV moat intact-to-strengthening near-term (dosing edge + LOE deferral) → Switching Costs held at 70, Cost Advantage 72. Competitive threat level: moderate; share trajectory: stable. The live vector is Merck's once-weekly oral (2027+), carried into the §11 Bear and §12 thesis-invalidation.
ROIC & capital allocation: ROIC ~20% (> WACC ~9%). Capital allocation is disciplined on returns (10-yr ~6.7% dividend CAGR, ~43% payout, $5.9B returned in 2025) but M&A is mixed (Immunomedics/Trodelvy $21B has under-delivered; CymaBay/Livdelzi looks better). Management skin-in-the-game is modest (typical for large pharma). FMP financial-health rating B+ (DCF/ROE/ROA sub-scores 5/5; dragged only by the D/E and P/E sub-scores — i.e. leverage and a low multiple, not quality).
Scored primarily off the warranted-multiple anchor (rate + disciplined growth), cross-checked against sector median, own history, FCF yield and the analyst consensus.
| Lens | Value | Read |
|---|---|---|
| FY27-forward P/E | ~13.5x | Attractive vs pharma peers (~15-16x) |
| Trailing P/E (TTM) | 17.7x | Fair — GAAP depressed by acquired-IPR&D charges (understates) |
| FCF yield (FCF/EV) | ~5.8% | Attractive (5-8%) |
| Dividend yield | 2.45% ($3.22) | ~43% payout — sustainable; outlier income for biotech |
| EV/EBITDA (TTM) | 12.7x | Reasonable |
| Own 5-yr history | Mid-to-upper of its own range | Richer vs its own HCV-decline lows — the one lens that isn't cheap |
PEG: FMP PEG (TTM) 0.32 is flattered by the rebound base; on normalised mid-single-digit growth the PEG is ~1.5x — fair-to-cheap, not a screaming bargain. Reverse-DCF / implied growth: at $131.27 the price embeds roughly 2-3% long-run EPS growth; our disciplined estimate is ~7% — the market is paying for less growth than the durable HIV franchise + lenacapavir ramp support, which is the crux of the Attractive read.
Analyst consensus: price $131.27 vs consensus target $161.81 (median $165, high $180, low $122) — +23% upside, i.e. price > 20% below consensus → strong valuation support. Grades: 38 Buy / 19 Hold / 1 Sell (Buy consensus, 65.5% bullish; the 19 holds show some hesitation). Coverage deep (42 targets in the last year), though only 6 issued last quarter — mild recency discount. FMP rating B+ corroborates.
Primary driver: HIV-franchise durability + lenacapavir prevention ramp + pipeline, versus drug-pricing policy (IRA). This is not a commodity name, so no price-trend overlay applies — the driver is the trajectory of the HIV moat and the reimbursement backdrop.
| Horizon | Read | Score |
|---|---|---|
| Historical (25%) | Biktarvy grew ~13% to $13.4B; lenacapavir approved & launched; franchise durable | 72 |
| Current (50%) | Biktarvy LOE pushed 2033 → 2036 (major de-risk); Yeztugo launching strongly (prevention +47% YoY, ~90% payer coverage). Offsets: Trodelvy lung-trial fail; IRA Medicare price negotiation live | 70 |
| Forward (25%) | Lenacapavir peak > $5B; 7 HIV launches through 2033; deep pipeline. Capped by IRA pricing overhang | 70 |
Driver score = 0.25x72 + 0.50x70 + 0.25x70 = 71 → Tailwind. Eligible to amplify a BUY to STRONG BUY only if Economic-Alignment pressure is also Tailwind — it is Neutral here, so no amplification fires and the base BUY stands at every horizon. Thesis-invalidation floor: the case breaks if HIV revenue turns to sustained decline — from an IRA price cut biting harder than modelled, or Merck's once-weekly oral taking material treatment share post-2027.
Regime Contested (Soft Landing / Stagflation co-lead 30/30). Health Care in XLV = Neutral/Neutral/Neutral — defensive, out of favour, low macro sensitivity (pharma cares more about pipeline & pricing policy than the sector map). Not in the AI cohort, so no systemic AI-unwind tail is inherited. Pressure = Neutral, so the driver Tailwind (71) cannot amplify the base BUY to STRONG BUY.
Source: sector-map · Macro report 2026-07-03
Timing = 65 (Improving). A genuine 200-DMA reclaim, not an established uptrend — read it as recovery, not momentum leadership.
| Sub-signal | Read | Score |
|---|---|---|
| MTF trend (30%) | Tool reads "strongly bullish"; monthly/weekly/daily up, hourly strong. Tempered: weekly close $131.27 is below its 20-wk SMA ($135) | 74 |
| Risk-reward (20%) | 1 Jul reclaimed the ~$130 50/200-DMA cluster (+4.2% day); stop at $115 is ~12% away — moderate | 62 |
| Relative strength | GILD ~-6% over 3 months; XLV out of favour — a laggard's bounce, not sector leadership | 50 |
| Macro overlay (10%, low HC sensitivity) | Fed on hold, VIX 16.6 (neutral), sector Neutral | 50 |
| Sentiment (20%) | Grades net flat (Maxim upgrade May; mostly maintains); news mixed (liver/HIV positive, oncology negative) | 60 |
| Catalyst (20%) | No stock-specific catalyst inside 30 days; Q2 earnings ~early Aug (calendar unconfirmed) | 68 |
Net: the tape has turned up off a base, but this is a reclaim of the mean rather than a breakout to leadership. Enough to keep the base signal a BUY at every horizon; not enough to force a STRONG read even before the amplification block.
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-07-14 | CPI YoY (Jun) | High | 3.9% | 4.2% | Indirect | Inflation/IRA pricing backdrop; low direct HC impact |
| 2026-07-29 | Fed Rate Decision | High | 3.75% | 3.75% | Indirect | Sets the discount rate in the valuation anchor; defensive pharma low sensitivity |
| 2026-07-30 | Core PCE MoM (Jun) | High | 0.3% | 0.3% | No | Minimal direct pharma impact |
| ~2026-08-06 | GILD Q2 earnings (est.) | High | - | - | Yes | Stock-specific — the key catalyst; date unconfirmed (calendar empty) |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-07-02 | Non-Farm Payrolls (Jun) | 57K | 110K | -48% below | Weak labour print, risk-off; defensive pharma relatively insulated |
| 2026-07-02 | Unemployment (Jun) | 4.2% | 4.3% | below | Marginally better than feared |
| 2026-07-01 | ISM Manufacturing (Jun) | 53.3 | 54 | below | Softening growth |
| 2026-06-30 | Consumer Confidence (Jun) | 91.2 | 94.4 | below | Soft — supports the defensive-sector case |
Health Care is a low-macro-sensitivity sector, so none of these releases is a high-impact driver for GILD; they set the regime backdrop (Contested; soft June payrolls) rather than the stock. The only stock-specific catalyst is Q2 earnings in early August — beyond the 14-day window, so the next refresh is the default +14d (2026-07-17).
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend up | Bullish | 62 | +, flat | S: 119 R: 157 | Resist. breakout | 0.1x |
| Weekly | Uptrend up | Neutral | 50 | -, falling | S: 116 R: 143 | None (below 20-wk SMA) | 0.9x |
| Daily | Uptrend up | Bullish | 58 | +, turning up | S: 122 R: 137.5 | 200-DMA reclaim | 0.85x |
| Hourly | Strong Up | Bullish | 64 | +, rising | S: 125 R: 131.6 | Breakout | - |
| 15-min | Strong Up | Bullish | 64 | +, flat | S: 125 R: 131.6 | Breakout | - |
| Confluence: Mostly Bullish · MTF Score 74 | |||||||
The tool flags "strongly bullish" confluence, but read it with nuance: monthly and daily are up and the stock reclaimed its 200-DMA ($129.9) on 1 Jul with a +4.2% day, yet the weekly close ($131.27) is still below its 20-week SMA ($135) and the stock sits ~16% under its Feb high ($157.29). This is a recovery / mean-reclaim within a broad range, not a breakout to new leadership. Key levels: hold $122-124 daily support and the $130 MA cluster to keep the reclaim valid; overhead resistance at $137.5 then the $157 high.
GILD daily, ~4 months. The 1 Jul reclaim of the ~$130 50/200-DMA cluster off the June $121 low; overhead resistance $137.5 then the Feb high $157.29; hard-stop reference $115.
Yeztugo ramp beats the (conservative) $800M guide, lenacapavir once-weekly oral treatment advances, the PBC/liver franchise scales, and the market re-rates a de-risked HIV cash engine toward ~18x on rising EPS. ~+41%.
HIV franchise durable (Biktarvy to 2036), lenacapavir prevention ramps steadily, EPS grinds toward ~$9.7 (FY27), and the multiple drifts up toward the pharma peer ~15-16x — roughly the $158-165 analyst zone. ~+20%; the probability-weighted centre of gravity.
IRA Medicare price cuts bite harder than modelled, oncology keeps disappointing, Yeztugo underwhelms, and Merck's once-weekly oral erodes future HIV treatment share — the multiple de-rates back toward the 52-week low ($107.75). ~-16%. This bear carries the live competitive trigger (Merck oral / IRA share).
Probability-weighted fair value approx $154 (0.25x185 + 0.55x158 + 0.20x110), ~17% above the $131.27 price — consistent with the Attractive valuation read and the +23% gap to consensus.
Forecast: Fundamental group is already met — a Half-Size starter is actionable now at ~$131. The Technical group needs a volume-confirmed (>1.5x) close holding above the $130 50/200-DMA cluster — plausible within ~1-3 weeks if the 1 Jul reclaim sticks, but a pullback resets the clock; more likely to confirm around Q2 earnings (~early Aug). The Catalyst group is earnings-dependent (early Aug). Realistic path to Full-Size: a post-earnings volume breakout, roughly 5 weeks out. CONFIDENCE: Moderate.
Forecast: Stop unlikely in the next 4-6 weeks — price is ~12% above the $115 stop and just reclaimed the 200-DMA. Thesis-invalidation legs are dormant (no guidance cut; Biktarvy LOE deferred to 2036; Merck's once-weekly oral is a 2027+ threat). The profit-target needs a ~26% move to $165 with an overbought RSI — not near-term.
What you're risking: ~$16/share (-12%) down to the hard stop, and the bear path to ~$110 (-16%) if IRA pricing or Merck's oral bite. You'd be entering on the Fundamental group alone — the Technical group is NOT yet volume-confirmed, so you're buying a fresh reclaim, not a proven breakout. What you're gaining: the base-case +20% you start capturing at a ~13.5x FY27 P/E, the 2.45% dividend while you wait, and the lenacapavir/PBC embedded optionality you own for free. Risk-reward ~1.7:1 to base, ~3.4:1 to bull. Read: acting now is reasonable as a starter; waiting for a volume-confirmed breakout (or Q2 earnings) upgrades conviction to Full-Size but costs you the first leg.
What you're giving up: the base-case move to ~$158, the dividend/compounding, and the lenacapavir prevention + once-weekly-oral optionality — while selling ~17% below probability-weighted fair value ($154). What you're protecting: capital if the IRA/oncology/Merck bear plays out toward $110. Is a rule triggered? No — no hard stop, no thesis-invalidation, no profit-target is live right now. Read: there is no mechanical reason to sell or stay out here; this is a hold/accumulate zone, not an exit.
Position sizing not computed — specify your portfolio allocation and role for sizing guidance.
{
"ticker": "GILD",
"date": "2026-07-03",
"version": "v6",
"exchange": "NASDAQ",
"exchange_ticker": "NASDAQ:GILD",
"isin": "US3755581036",
"api_ticker": "GILD",
"analysis_status": "on-going",
"finder_ticker": "GILD",
"finder_exchange": "\ud83c\uddfa\ud83c\uddf8 NASDAQ",
"finder_section": "Health Care",
"user_horizon": null,
"user_allocation_pct": null,
"portfolio_role": null,
"lifecycle_stage": "mature",
"price_at_rating": 131.27,
"signal_short": "BUY",
"signal_medium": "BUY",
"signal_long": "BUY",
"primary_signal": "BUY",
"quality_score": 74,
"quality_detail": {
"industry_benchmark_name": "R&D efficiency + patent-cliff exposure",
"industry_benchmark_value": "Biktarvy LOE 2036; low 3-yr cliff",
"industry_benchmark_score": 72,
"moat_score": 68,
"roic_percentile_vs_peers": 75,
"capital_allocation": 60,
"management_skin_in_game": 55
},
"valuation_score": 72,
"valuation_detail": {
"fcf_yield": 5.8,
"implied_growth_rate": 2.5,
"consensus_growth_rate": 9.0,
"historical_valuation_decile": 6
},
"warranted_multiple": 20.4,
"actual_multiple": 13.5,
"val_multiple_basis": "FY27 consensus forward P/E (EPS $9.70)",
"discount_rate_r": 9.0,
"risk_free_10y": 4.48,
"g_near": 7.0,
"g_term": 3.0,
"warranted_ratio": 0.66,
"val_band": "attractive",
"nonop_pct_of_net_income": 0,
"clean_pe": 13.5,
"clean_peg": 1.5,
"timing_score": 65,
"timing_detail": {
"mtf_confluence": 74,
"risk_reward_score": 62,
"relative_strength_vs_spy": -6.0,
"relative_strength_vs_sector": -1.0,
"catalyst_clustering_score": 68,
"dynamic_macro_weight": 0.1
},
"driver_score": 71,
"driver_label": "Tailwind",
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 52,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-07-03",
"competitive_share_trajectory": "stable",
"competitive_threat_level": "moderate",
"overall_confidence": 68,
"fair_value_est": 158,
"stop_loss": 115,
"target_price": 158,
"scenario_base_target": 158,
"scenario_bull_target": 185,
"analyst_consensus_target": 161.81,
"analyst_target_high": 180,
"analyst_target_low": 122,
"analyst_target_upside_pct": 23.3,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 65.5,
"analyst_coverage_count": 58,
"fmp_rating": "B+",
"fmp_overall_score": 3,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"hard_gate_state": "clear",
"entry_groups_met": 1,
"entry_conviction": "Half-Size",
"exit_groups_live": 0,
"exit_action": "Hold",
"gates_triggered": [],
"do_not_buy_triggers": [],
"next_update_date": "2026-07-17",
"next_update_basis": "default +14d (no stock-specific event <14d; Q2 earnings ~early Aug, calendar unconfirmed)"
}